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Abstract
Background: Abdominal obesity, atherogenic dyslipidemia and hypertension are essential risk factors for
cardiovascular diseases. Several studies showed favorable effects of weight loss in overweight subjects on
cardiometabolic risk profile.
Methods: This open-label, randomized, controlled study investigated the effect of an energy-restricted modified
diet with (MR) or without meal replacements for weight control (C) on weight loss, body composition and
cardiometabolic risk profile in overweight women. Of 105 randomized participants, 87 were eligible for per
protocol analysis. Anthropometric, clinical, blood, 24 h-urine parameters and dietary intake were assessed at
baseline and after 12 weeks.
Results: Dietary intervention resulted in a significant weight loss in both groups (MR: -5.98 ± 2.82 kg; p < 0.001, C:
-4.84 ± 3.54 kg; p < 0.001). However, the rate of responder (weight loss >5%) was higher in MR (77%) versus C
group (50%) (p = 0.010). A significant reduction in waist circumference (WC) and body fat mass (BFM) was
observed in both groups. Body cell mass (BCM) and lean body mass (LBM) decreased, while percentage of BCM of
body weight increased in MR more than in C group. Systolic and diastolic blood pressure (BP) significantly
decreased and to a similar extent in both groups. Total cholesterol (TC), LDL-C but also HDL-C declined
significantly in both groups, while no change occurred in triglycerides.
Conclusions: Both dietary intervention strategies had a similar effect on weight loss and body fat distribution, but
rate of responder was significantly higher in MR group. Systolic BP decreased to a similar extent in both groups.
Cardiometabolic risk profile improved only partly in both groups.
Introduction
The rising prevalence of obesity is considered a major
cause for disorders such as type 2 diabetes (DM2) and
cardiovascular diseases [1,2]. Type of body fat distribu-
tion seems to play a crucial role in the pathogenesis of
obesity-related diseases. Due to its higher endocrine and
metabolic activity compared to subcutaneous adipose
tissue, visceral adipose tissue is regarded as a predictor
of cardiometabolic risk factor levels [2-6]. Abdominal
obesity is strongly correlated with visceral adipose tissue,
clinically represented by the measurement of waist cir-
cumference (WC) [7]. A population-based cohort study
of diabetes revealed that a larger waist circumference is
associated with a higher risk of DM2, especially in
women, whereas larger hip and thigh circumferences are
clearly associated with a lower risk of diabetes [8].
The widespread lipid disorder in visceral obesity, insu-
lin resistance and metabolic syndrome is atherogenic
dyslipidemia, which is characterized by triad of elevated
serum triglycerides (TG), low HDL-cholesterol (HDL-C)
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favorable effects of visceral weight loss on serum TG in
overweight subjects [4,9,10].
The question is whether the achieved weight loss alone
is responsible for the reduction in blood pressure. Besides
weight loss, mental stress reduction, dietary sodium
restriction, and an increased intake of dietary flavanoids
are suggested to reduce blood pressure [11-13]. Weight
loss can be achieved by a conventional structured
energy-restricted modified diet alone or in combination
with meal replacements for weight control. Recent
reports indicated that such meal replacements coupled
with a low-calorie diet can offer an effective option for
weight reduction and improvements in metabolic risk
factors in overweight patients [14-16]. Therefore, aim of
this prospective randomized study was to evaluate
whether a diet with meal replacements (MR) can be as
effective as a conventional energy-restricted modified
diet (control diet, C) on weight loss, body composition
and cardiometabolic risk profile in overweight women.
Methods
Participants
Overweight women were recruited from two outpatient
centers for nutrition education in Frankfurt/M and Ber-
lin, Germany. Women aged between 18 and 60 years,
BMI between 27.0 and 34.9 kg/m
2 and with one of the
following blood lipids were included into the study: total
cholesterol (TC) ≥ 200 mg/dL, LDL-cholesterol (LDL-C)
≥ 175 mg/dL, HDL-C ≤ 50 mg/dL, TG 150-400 mg/dL.
Exclusion criteria were lactose or protein intolerance,
hypo- or hyperthyroidism, pharmacological treatment of
diabetes, intake of vitamins or mineral supplements,
anticoagulants, cardiac pacemaker and contraindications
to exercise. One hundred and thirteen subjects were
screened (Figure 1). The study was approved by the
ethics committees of the Chamber of Physicians of the
German federal states of Hessen and Berlin. Informed
consent was obtained from each participant prior to
study onset.
Study design
In a 12-week open-label, randomized, controlled inter-
vention trial, subjects were randomly assigned to the
MR or the C group, respectively, by a computer-gener-
ated identification number in order of recruitment.
Blood samples, dietary records, clinical and biochemical
data were collected at baseline and repeated 12 weeks
after dietary intervention. Primary end point of the
study was weight loss. The planned sample size of 44
subjects per group, excluding drop-out rate, was based
on a power of 80% to detect a difference of at least 2.0
± 3.0 kg (mean ± SD) between both groups at a level of
significance of a = 0.05.
Both dietary intervention groups were instructed to
follow an energy-restricted diet of approximately 1200
kcal/d. Three meals (breakfast, lunch, and dinner) were
recommended. The food choice was based on vegeta-
bles, fruits, whole grain cereal and low-fat dairy pro-
ducts (1.5% fat). The MR group was advised to replace
two meals, i.e. breakfast and dinner, every day with two
MR shakes, soups or bars (FormMed HealthCare AG,
Frankfurt/M, Germany) and to prepare their own lunch.
T h ee n e r g yp e rs e r v i n go ft h eM Rm e a li ss h o w ni n
Table 1. Each MR represented a balanced diet product
for weight reduction according to article 14a of the diet-
ary regulation issued by the German Federal Ministry of
Food, Agriculture and Consumer Protection, based on
Commission Directive 1996/8/EC of 26 February 1996.
The C group was advised to follow a conventional
energy-restricted modified diet with 15-20% of energy
intake in the form of protein, 50-55% of energy intake
in the form of carbohydrates and approximately 30% of
energy intake in the form of fat according to previous
studies [15,17].
During a 12-week intervention period all participants
attended ten group training sessions (eight to ten
women per class) and four face-to-face visits for nutri-
tion education. All participants received instruction
manuals that included a sample meal plan, recipes and
information regarding physical activity. Group training
lasted one hour per session. Group training sessions
were held separately for each group by a nutrition advi-
sor. Topics of the structured sessions included practical
knowledge of food, portion sizes and meal frequency
with the aim of changing dietary behavior and lifestyle.
Group MR 
(n = 51) 
Group C 
(n = 54) 
Randomized (n = 105) 
Group MR 
(n = 43) 
Group C 
(n = 44) 
Withdrawal 
(n = 8)
1
Withdrawal 
(n = 10)
Completed (n = 87) 
1one adverse effect 
abbreviations used: MR, meal replacement; C, control 
Screened (n = 113) 
Excluded (n = 8) 
Figure 1 Trial profile.
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was 25 minutes (range 10-40 minutes).
At baseline women were instructed on food selection,
portion size estimation and accurate recording of dietary
intakes. Three-day food records were documented at base-
line and after the 12-week intervention. Dietary records
were reviewed with each study participant and analyzed
using PRODI 5.3 software (WVG, Stuttgart, Germany).
Body weight (kg) and height (cm) were measured.
WC, HC and thigh circumference was determined via
flexible tape. The goal to achieve > 5% weight loss was a
targeted value. Body fat mass (BFM), body fat (%), body
cell mass (BCM), and lean body mass (LBM) were
determined by bioelectrical impedance analysis (BIA)
with biaform
® software version 2.2 under standardized
conditions [17]. Blood pressure (BP) was measured
under standardized conditions after a 10 min. resting
period. Anthropometric measurements and venous
blood sampling were performed in the morning after an
overnight fasting period of at least 12 h. Due to analysis
of serum cortisol, blood samples were taken at 9:00 a.m.
At baseline and after the 12-week dietary intervention,
24-hour urines were collected.
Laboratory methods
Analyses of serum glucose (hexokinase method), uric
acid (uricase-PAP method), gamma-glutamyltransferase
(kinetic color test IFCC), total cholesterol (TC) (CHOD-
PAP method), LDL-C and HDL-C (enzymatic color
test), TG (GPO-PAP method) on Olympus 600 analyzer,
homocysteine, folic acid and cortisol (chemiluminiscence
method) on ADVIAR Centaur analyzer and glycated
hemoglobin (HbA1c) (HPLC) on Biorad Variant II ana-
lyzer were conducted by the medical laboratory Pots-
dam, Germany.
Determination of the total antioxidative capacity
(TAC) was performed by the reaction of antioxidants in
the sample with a defined amount of exogenously pro-
vided hydrogen peroxide (H2O2). The antioxidants in
the sample eliminate a certain amount of the provided
hydrogen peroxide. The residual H2O2 is determined
photometrically by an enzymatic reaction which involves
the conversion of TMB to a colored product.
Analysis of 24 h urinary sodium excretion (ion sensi-
tive electrode (ISE)) was performed at the laboratory of
Medical Nutrition Science, Department of Urology, Uni-
versity of Bonn, Germany.
Laboratory quality certification was available for each
parameter except for homocysteine, folic acid and TAC.
Statistical methods
Statistical comparisons between groups were performed
using the nonparametric Mann-Whitney U test for
unpaired data. Pre-post intervention changes were ana-
lyzed via non-parametric Wilcoxon test. All statistical
tests were two-sided. Differences were considered signif-
icant at p < 0.05. Data are reported as mean ± standard
deviation (SD). ANCOVA including use of weight
change and age as covariates was used to control for the
potential confounder of systolic BP. Data analysis was
performed based on the per protocol population and by
using SPSS
® for Windows (version 19.0).
Results
Participants
A total of 105 overweight women were randomized, of
whom 87 were eligible for per protocol (PP) analysis
Table 1 Daily dietary intake with meal replacements (per
serving size)
Shake Soup Bar
Energy (kcal) 205 200 218
Protein (g) 19 21.9 17.2
Carbohydrates (g) 16.9 12.9 27.0
Fat (g) 5.9 6.6 6.8
Fatty acids
SAFA (g) 2.6 0.9 2.2
LA (g) 1.0 3.1 2.2
MUFA (g) 1.1 1.35 2.4
Dietary fibre (g) 2.4 1.5 3.1
Minerals
Sodium (mg) 180 900 183
Potassium (mg) 510 605 539
Magnesium (mg) 200 61 82
Calcium (mg) 525 300 329
Phosphate (mg) 357 208 279
Iron (mg) 7.5 4.9 8
Zinc (mg) 5.0 3.0 7.4
Manganese (mg) 0.6 0.4 1.5
Copper (mg) 0.7 0.4 1.0
Iodine (μg) 75 41 75
Selenium (μg) 36 16.5 27
Vitamins
Vitamin A (μg) 400 210 600
Vitamin B1 (mg) 0.7 0.3 0.8
Vitamin B2 (mg) 1.2 0.5 0.9
Vitamin B6 (mg) 1.0 0.5 1.1
Vitamin B12 (μg) 1.5 0.4 1.7
Vitamin C (mg) 45 13.5 34
Vitamin D (μg) 2.5 1.5 2.9
Vitamin E (mg) 10 3.0 11.5
Biotin (μg) 75 4.5 86
Folic acid (μg) 150 60 115
Nicotinic acid (mg) 12 5.4 10
Pantothenic acid (mg) 3.0 0.9 5.7
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due to adverse effects (diarrhea) in the MR group and
11 for personal reasons (four women in the MR and
seven women in the C group). Additionally, six women
h a dt ob ee x c l u d e df r o ma n a l y s i sd u et op r o t o c o lv i o l a -
tions. Meal replacements were well tolerated by the
patients.
No differences were observed at baseline between both
groups regarding anthropometric, clinical and biochem-
ical parameters. Fifty-nine women (67.8%) had obesity
stage I (Table 2). The ratio of obesity stage I (30.0-34.9
kg/m
2) to preobesity (27.0-29.9 kg/m
2) was approxi-
mately 2:1 in both groups. Abdominal adipose tissue
distribution type (WC > 88 cm) did not differ between
the MR and the C group. Systolic blood pressure (130/
80 mmHg) was slightly above the cutoff in the MR
group [3].
Anthropometric and clinical characteristics
Dietary intervention resulted in a significant weight loss
in both groups, without significant difference between
the MR and the C group (Table 3). However, relative
weight loss in the MR group was higher compared to
the C group (p = 0.048). Moreover, the rate of respon-
der (>5% weight loss) was higher in the MR group (33
women, 77%) versus the C group (22 women, 50%) after
the 12-week dietary intervention (p = 0.010) (Table 4).
While women with WC ≤ 88 cm (21.8% in both groups)
lost significantly more weight in the MR group (MR: -
5.98 ± 2.28 kg, C: - 0.96 ± 2.29 kg; p = 0.002), no signif-
icant difference in weight change was observed in
women with WC > 88 cm (MR: -5.98 ± 3.04 kg, C: -
5.57 ± 3.25 kg; p = 0.506).
Dietary intervention significantly reduced mean BMI
from obesity stage I to preobesity in both groups (Table
3). Correspondingly, WC and waist-to-height ratio
(WHtR) significantly decreased to a similar extent. After
the 12-week dietary intervention, mean WC was below
t h ec u t o f fo f8 8c mo n l yi nt h eM Rg r o u p[ 3 ] .W i t h i n
group analysis revealed a significant reduction in BFM,
body fat (%), BCM, and LBM in both groups. After the
12-week dietary intervention, mean systolic and diastolic
BP were within the normal range.
Clinical chemistry and biochemical characteristics
After the 12-week dietary intervention TC, LDL-C but
also HDL-C significantly decreased in both groups,
without significant differences between the groups
(Table 5). No change was observed in serum TG, glu-
cose and uric acid within and between groups during
intervention. Serum homocysteine concentration
increased significantly only in the C group, but this was
without clinical relevance. Serum folic acid concentra-
tion increased significantly only in the MR group.
Serum cortisol concentration and TAC remained
unchanged during the intervention period. GGT activity
decreased significantly inb o t hg r o u p st oas i m i l a r
extent.
Cardiometabolic risk profile
Table 4 reflects results related to the cardiometabolic
risk profile. The total number of subjects classified with
atherogenic dyslipidemia [3] did not reduce significantly
during the study. After the 12-week dietary intervention
hypertriglyceridemic waist phenotype, i.e. WC > 88 cm
and TG ≥ 150 mg/dL [18], decreased by 42% in the MR
group and by 50% in the C group.
Dietary intake
At baseline, the reported energy intake was similar in
both groups (MR: 1574 ± 408 kcal/d; C: 1683 ± 414
kcal/d). After the 12-week intervention energy intake
was significantly reduced within each group but not
between both groups (MR: 1268 ± 306 kcal/d; C: 1406 ±
392 kcal/d). The calculated energy expenditure esti-
mated with Harris-Benedict equation [19] at a physical
activity level (PAL) of 1.6 differed from these data in
both groups at baseline (MR group: 2356 ± 191 kcal/d
C group: 2378 ± 163 kcal/d) and therefore suggested
Table 2 Baseline characteristics of overweight women in
the meal replacement (MR) and control group (C),
respectively
MR
(n = 43)
Mean ± SD
C
(n = 44)
Mean ± SD
MR vs C
P
Age (years) 49.8 ± 11.7 49.6 ± 11.0 0.776
a
Weight (kg) 83.9 ± 8.8 84.1 ± 8.3 0.946
a
Height (cm) 163.8 ± 5.9 164.0 ± 5.8 0.909
a
BMI (kg/m
2) 31.2 ± 2.3 31.2 ± 2.1 0.912
a
BMI 27.0 - 29.9 kg/m
2 (n) 14 (32.6%) 14 (31.8%) 0.941
b
BMI 30.0 - 34.9 kg/m
2 (n) 29 (67.4%) 30 (68.2%) 0.941
b
WC (cm) 93.9 ± 7.2 94.9 ± 6.1 0.491
a
WC 80 - 88 cm (n) 12 (27.9%) 7 (15.9%) 0.176
b
WC > 88 cm (n) 31 (72.1%) 37 (84.1%) 0.176
b
BP systolic (mmHg) 131.2 ± 17.4 128.0 ± 19.7 0.185
a
BP systolic ≥ 130 mmHg (n) 27 (62.8%) 22 (50.0%) 0.229
b
BP diastolic (mmHg) 80.8 ± 9.6 79.8 ± 9.0 0.321
a
BP diastolic ≥ 85 mmHg (n) 16 (37.2%) 11 (25.0%) 0.218
b
Heart rate (1/min) 76.6 ± 10.6 77.8 ± 10.8 0.792
a
Heart rate > 70/min (n) 33 (76.7%) 34 (77.3%) 0.953
b
Oral contraceptives (n) 5 (11.6%) 3 (6.8%) 0.438
b
Smokers (n) 7 (16.3%) 9 (20.5%) 0.615
b
abbreviations used: BMI, body mass index; BP, blood pressure; WC, waist
circumference
aMann-Whitney-U-test
bChi
2-Test
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from 24 h urinary sodium excretion.
Discussion
Our results indicate that both weight loss strategies are
effective treatment options for overweight women. The
goal to achieve a weight loss of more than 5% (4.2 kg of
mean body weight at baseline) after 12 weeks was
exceeded by at least 1.8 kg in the MR group but only by
0.6 kg in the C group, which is reflected in the signifi-
cantly increased responder rate of the MR group. These
results can be attributed to the preference for conveni-
ence foods [20] The weight loss of approximately 5%
achieved in both groups is similar to that reported for
preobesity and obesity stage I [14-16,21]. It has been
reported that especially time and structure of the nutri-
tional education play an important role in achieving
high compliance [14]. Moreover, regular education to
achieve an increase in physical activity is necessary,
especially for maintaining the body weight [22].
For the evaluation of cardiometabolic risk not only
body weight is important. The role of the body fat dis-
tribution phenotype has been shown to be even more
prominent than that of BMI [23]. Compared to visceral
fat, a high proportion of subcutaneous fatty tissue is
accompanied by a lower cardiometabolic risk. Therefore,
reduction in WC is considered to be more essential
than loss of body weight alone, especially in DM2 [24].
Studies have shown that WHtR is the best indicator of
cardiovascular risk in different measures of abdominal
obesity and that it can be used to assess body composi-
tion [25]. In the present study, the significant decrease
in WC and WHtR in both groups during dietary inter-
vention suggests that the body fat distribution pheno-
type has changed. A general cutoff of 0.5 has been
suggested for WHtR [26]. However, this value was not
achieved in our study population.
A strong association has been demonstrated between
WC and plasma TG [27]. After the 12-week dietary
intervention a decrease in WC by 6.6 cm in the MR
Table 3 Anthropometric and clinical characteristics in overweight women at baseline and after dietary intervention
MR (n = 43)
Mean ± SD
C (n = 44)
Mean ± SD
MR vs C
Baseline Week 12 Difference Baseline Week 12 Difference P
a
Weight (kg) 83.9 ± 8.8 78.0 ± 9.2** -5.98 ± 2.82 84.1 ± 8.3 79.3 ± 7.3** -4.84 ± 3.54 0.075
Relative weight loss (%) 100 ± 0 92.8 ± 3.3** -7.19 ± 3.25 100 ± 0 94.4 ± 4** -5.60 ± 4.02 0.048
BMI (kg/m
2) 31.2 ± 2.3 29.0 ± 2.6** -2.24 ± 1.02 31.2 ± 2.1 29.4 ± 1.9** -1.79 ± 1.31 0.075
WC (cm) 93.9 ± 7.2 87.4 ± 7.6** -6.55 ± 3.91 94.9 ± 6.1 89.6 ± 6.3** -5.30 4.27 0.094
WHtR 0.574
± 0.043
0.534
± 0.047**
0.040
± 0.024
0.579
± 0.040
0.547
± 0.045**
0.032
± 0.026
0.092
HC (cm)
b 114.2 ± 6.4
(n = 26)
108.5 ± 6.0 -5.71 ± 2.34 114.3 ± 6.0
(n = 28)
109.4 ± 6.5 -4.93 ± 3.45 0.565
WHR
b 0.83 ± 0.06
(n = 26)
0.82 ± 0.05 -0.01 ± 0.03 0.84 ± 0.05
(n = 28)
0.84 ± 0.06 0.00 ± 0.03 0.350
Thigh circumference (cm)
b 64.1 ± 5.0 60.8 ± 5.1 -3.33 ± 2.10 64.1 ± 4.6 61.5 ± 5.0 -2.59 ± 2.35 0.158
(n = 35) (n = 38)
BFM (kg) 36.1 ± 6.3 31.4 ± 6.4** -4.69 ± 2.31 36.6 ± 6.0 32.6 ± 5,2** -3.98 ± 2.53 0.144
Body fat (%) 42.7 ± 3.8 39.9 ± 4.3** -2.79 ± 1.79 43.3 ± 3.6 41.0 ± 3.6* -2.33 ± 1.51 0.191
BCM (kg) 25.7 ± 2.5 24.8 ± 2.6** -0.93 ± 0.80 25.7 ± 2.3 24.7 ± 2.0** -0.98 ± 0.98 0.760
BCM (%) 30.8 ± 2.9 32.0 ± 3.1** 1.19 ± 1.24 30.7 ± 3.0 31.3 ± 2.9* 0.62 ± 1.17 0.054
LBM (kg) 48.1 ± 3.8 46.8 ± 3.9** -1.30 ± 1.40 47.7 ± 3.8 46.9 ± 3.3** -0.77 ± 1.46 0.058
LBM (%) 57.6 ± 3.8 60.4 ± 4.3** 2.81 ± 2.22 56.9 ± 3.7 59.4 ± 3.7** 2.45 ± 1.93 0.445
BP systolic (mmHg) 131.2 119.8 -11.4 128.0 119.5 -8.5 0.148
± 17.4 ± 12.8** ± 18.8 ± 19.7 ± 13.8* ± 23.5
BP diastolic (mmHg) 80.8 ± 9.6 77.2 ± 8.6* -3.6 ± 11.7 79.8 ± 9.0 75.5 ± 8.3* -4.4 ± 11.7 0.914
Heart rate (1/min)
b 77.0 ± 10.3
(n = 42)
75.8 ± 9.9 -1.2 ± 8.0 77.8 ± 10.8 75.8 ± 11.5 -2.0 ± 8.9 0.983
abbreviations used: BCM, body cell mass; BFM, body fat mass; BMI, body mass index; BP, blood pressure; C, control group; HC, hip circumference; LBM, lean body
mass; MR, meal replacement group; WC, waist circumference; WHR, Waist-to-hip ratio; WHtR, Waist-to-height ratio
*p < 0.05; ** p < 0.001; Wilcoxon-test within groups
ap-value: Mann-Whitney-U-test
bdata not available for all women
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prisingly, in our study no significant reduction in fasting
serum TG and glucose was observed in the present trial.
In our study, a similar reduction of TC and LDL-C
was found in both groups, which can be attributed to
energy restriction and the resulting weight loss.
Although the significant decrease in HDL-C is remark-
able, mean HDL-C at baseline and after the 12-week
dietary intervention was above the cutoff of 50 mg/dL.
It is notable that the number of women with a HDL-C
below 50 mg/dL, TG above 150 mg/dL and atherogenic
dyslipidemia, respectively, did not change in both
groups. Although several studies found that weight
reduction in overweight and obese subjects favorably
modifies atherogenic dyslipidemia [28,29], we were
unable to confirm these findings. One reason could be
the fatty acid composition of the dietary intervention
with an insufficient proportion of MUFA and especially
long-chain n-3 polyunsaturated fatty acids (n-3 LC
PUFA).
Moreover, the 12-week dietary intervention resulted in
a significant and similar improvement of systolic and
diastolic BP in both groups. However, the number of
women with systolic BP ≥ 130 mmHg decreased signifi-
cantly only in the MR group and the number of women
with a BP of 130/85 mmHg tended to decrease after 12
weeks.
In the present study, body weight loss resulted in a
significant reduction in systolic BP in the study popula-
tion (p = 0.002) (Table 6). This effect depended on the
body weight at baseline. The higher the initial body
weight, the higher was the reduction in systolic BP and
diastolic BP. One kg of weight loss resulted in a reduc-
tion of systolic and diastolic BP by 2.0 and 1.1 mmHg,
respectively. The effect of weight loss on systolic BP was
more pronounced in the C group and amounted to 3.5
mmHg per kg body weight (p = 0.001) as compared to
1.0 mmHg per kg body weight in the MR group (p =
0.480). Diastolic BP was similar with 1.7 mmHg per kg
body weight in the C group (p < 0.001), and 0.4 mmHg
in the MR group (p = 0.545).
Apart from the influence of weight loss on the systolic
blood pressure, dietary sodium intake, estimated from
24 h urinary sodium excretion, seemed to exert different
effects on both groups. No convincing association was
found between systolic BP and serum cortisol and
between systolic BP and sodium intake (Table 6). Body
cell mass (BCM) and lean body mass (LBM) decreased
in both groups, while the percentage of BCM of body
weight increased more in the MR group than in the C
Table 4 Change in the cardiometabolic risk profile in overweight women after dietary intervention
MR (n = 43)
n (%)
C (n = 44)
n (%)
MR vs C
Baseline Week 12 P
a Baseline Week 12 P
a P
b
Weight reduction
>5 %
-3 3
(76.7%)
-- 2 2
(50.0%)
- 0.010
WC > 88 cm 31
(72.9%)
19
(44.2%)
0.009 37
(84.1%)
24
(54.5%)
0.003 0.429
BP systolic
≥ 130 mmHg
28
(65.1%)
15
(34.9%)
0.005 20
(45.5%)
12
(27.3%)
0.076 0.263
BP diastolic
≥ 85 mmHg
13
(30.2%)
9
(20.9%)
0.323 6
(13.6%)
6
(13.6%)
1.000 0.229
BP ≥ 130/85 mmHg 12
(27.9%)
5
(11.6%)
0.058 6
(13.6%)
5
(11.4%)
0.747 0.439
TG ≥ 150 mg/dl 14
(41.2%)
c
16
(47.1%)
c
0.651 15
(44.1%)
c
13
(38.2%)
c
0.647 0.897
HDL-C < 50 mg/dl 11
(32.4%)
c
12
(35.3%)
c
0.808 8
(23.5%)
c
11
(32.4%)
c
0.437 0.851
Fasting glucose
≥ 110 mg/dl
2
(5.9%)
c
2
(5.9%)
c
1.000 3
(8.8%)
c
1
(2.9%)
c
0.306 0.906
Hypertriglyceridemic
waist
d
12
(35.3%)
c
7
(20.6%)
c
0.194 14
(41.2%)
c
7
(20.6)
c
0.080 0.984
Atherogenic
dyslipidemia
e
6
(17.6%)
c
7
(20.6%)
c
0.763 4
(11.8%)
c
3
(8.8%)
c
0.694 0.490
abbreviations used: BP, blood pressure; C, control group; HDL-C, HDL cholesterol; MR, meal replacement group; WC, waist circumference
ap-value: chi-square-test within groups
bp-value: chi-square-test in contingency tables
cbiochemical analysis with the same method (n = 34)
dhypertriglyceridemic waist, i.e. WC > 88 cm and TG ≥ 150 mg/dL [18]
eatherogenic dyslipidemia, i.e. triad of elevated triglycerides, low HDL-C, and small LDL-C particles [3]
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B C Mi nt h eM Rg r o u pv e r s u sCg r o u pr e s u l t e di na
reduction in systolic BP, whereas BCM affected systolic
B Pi nt h eCg r o u po n l yv i aw e i g h tr e d u c t i o n( T a b l e6
and 7). The different changes in body composition and
the different impact of body weight are reflected in non-
BCM and BCM. The result from the C group shows
that non-BCM is the dominant factor for systolic BP
reduction, while BCM was found to be the major factor
in the MR group. The systolic BP decreased to a similar
extent in both groups despite different influencing
variables.
GGT is the enzyme responsible for initiating extracel-
lular catabolism of glutathione [30]. Increased GGT
activity may be a response to oxidative stress, which can
increase the transport of glutathione precursors into
cells [30,31] and is involved in the generation of reactive
Table 5 Clinical chemistry and biochemical characteristics in overweight women at baseline and after dietary
intervention
MR (n = 34)
a Mean ± SD C (n = 34)
a Mean ± SD MR vs C
Baseline Week 12 Difference Baseline Week 12 Difference P
b
Glucose (mg/dL) 91.8 ± 13.7 92.4 ± 10.9 0.63 ± 10.94 90.7 ± 14.3 88.1 ± 13.1 -2.66 ± 10.74 0.315
HbA1c (%) 5.54 ± 0.63 5.49 ± 0.47 -0.05 ± 0.64 5.63 ± 0.51 5.46 ± 0.48 -0.16 ± 0.61 0.201
TC (mg/dL) 241.2 ± 53.1 224.4 ± 53.2* -16.7 ± 33.7 241.5 ± 34.3 230.3 ± 40.9* -11.2 ± 25.9 0.556
HDL-C (mg/dL) 59.1 ± 16.1 55.3 ± 14.1** -3.7 ± 6.2 59.2 ± 11.5 55.7 ± 10.9* -3.5 ± 5.2 0.864
LDL-C (mg/dL) 157.0 ± 39.7 144.0 ± 38.4** -13.0 ± 18.2 161.4 ± 24.2 152.3 ± 30.8* -9.1 ± 18.7 0.647
TG (mg/dL) 186.4 ± 145.6 161.1 ± 108.0 -25.3 ± 110.4 152.5 ± 83.8 141.6 ± 66.1 -10.9 ± 52.9 0.861
TG/HDL-C 3.59 ± 3.55 3.19 ± 2.49 -0.40 ± 2.44 2.71 ± 1.66 2.62 ± 1.37 -0.09 ± 0.96 0.880
LDL-C/HLD-C 2.81 ± 0.86 2.73 ± 0.86 -0.08 ± 0.33 2.81 ± 0.63 2.79 ± 0.68 -0.02 ± 0.33 0.539
GGT (U/L) 33.5 ± 28.8 27.8 ± 20.1 -5.72 ± 12.91* 27.9 ± 13.3 24.0 ± 10.6 -3.85 ± 4.92** 0.759
Uric acid (mg/dL) 4.82 ± 1.18 4.59 ± 0.94 -0.23 ± 0.70 4.86 ± 1.01 4.75 ± 0.97 0.11 ± 0.66 0.384
Homocysteine
(μmol/L)
11.7 ± 4.1 11.0 ± 2.7 -0.63 ± 2.66 10.3 ± 2.0 11.7 ± 2.7* 1.36 ± 2.65 0.007
Folic acid (μg/L) 10.6 ± 4.9 15.2 ± 5.8** 4.62 ± 5.74 11.1 ± 4.3 12.3 ± 7.2 1.17 ± 6.28 0.005
GFR (mL/min/1.73 m
2) 73.6 ± 12.0 73.3 ± 12.1 -0.24 ± 6.50 74.8 ± 8.9 72.5 ± 8.8 -2.27 ± 6.10 0.202
TAC (μmol/L) 266.2 ± 30.8 276.6 ± 38.4 10.4 ± 45.6 280.9 ± 43.0 282.2 ± 45.7 1.3 ± 48.5 0.210
Cortisol (nmol/L) 424.3 ± 142.5 532.1 ± 179.6 107.8 ± 145.6 387.2 ± 164.6 477.4 ± 140.9 90.2 ± 176.0 0.826
TAC/Cortisol (10
3) 0.70 ± 0.27 0.58 ± 0.20 -0.12 ± 0.27 0.89 ± 0.49 0.65 ± 0.25 -0.24 ± 0.41 0.498
U-sodium (mmol/24 h)
c 162.2 ± 64.5 158.2 ± 94,1 -4.0 ± 118.0 158.3 ± 68.1 170.8 ± 81.2 12.5 ± 82.9 0.283
abbreviations used: GFR, glomerular filtration rate; GGT, gamma-glutamyltransferase; HbA1c, glycated haemoglobin; HDL-C, HDL cholesterol; LDL-C, LDL
cholesterol; TAC, total antioxidative capacity; TC, total cholesterol; TG, triglycerides; U-sodium, urinary sodium
abiochemical measurements with the same method
bp-value: Mann-Whitney-U-test; Wilcoxon-test within groups: *p < 0.05; **p < 0.001
cn = 26 in the MR group and n = 28 in the C group
Table 6 Systolic blood pressure depending on body
weight, sodium intake and serum cortisol (age-adjusted)
Body weight
Group Difference RC B P
C (n = 34) -5.0 ± 3.5 3.516 0.001
MR (n = 33) -6.6 ± 2.6 1.028 0.480
Urinary sodium
Group Difference RC B P
C (n = 34) 3.5 ± 70.6 -0.051 0.383
MR (n = 33) -29.7 ± 86.7 0.068 0.106
Serum cortisol
Group Difference RC B P
C (n = 34) 95.2 ± 164.6 0.041 0.105
MR (n = 33) 118.7 ± 159.1 -0.015 0.515
abbreviations used: C, control group; MR, meal replacement group; RC B,
regression coefficient B
Table 7 Systolic blood pressure depending on BCM and
non-BCM (age-adjusted)
Group P
ANCOVA
dnon-BCM dBCM
Total 0.005 2.257
(0.7 - 3.8)
0.004
0.135
(-4.8 - 5.1)
0.957
C 0.013 2.765
(0.5 - 5.0)
0.018
3.226
(-4.0 - 10.4)
0.372
MR 0.218 1.231
(-1.0 - 3.5)
0.278
-4.689
(-11.9 - 2.6)
0.198
abbreviations used: BCM, body cell mass; C, control group; d, difference; MR,
meal replacement group
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Page 7 of 9oxygen species [31]. Therefore, it has been suggested
that higher GGT levels are associated with an increased
risk for the development of hypertension [32]. In our
study, we found a significant reduction in GGT activity
in both groups.
Evidence suggests that reactive oxygen species are fun-
damentally involved in hyperhomocysteinemia, which,
together with a low folate status, is a major risk factor
for atherosclerosis [33]. In the present study, a signifi-
cant higher serum homocysteine was found after the 12-
week dietary intervention in the C group when com-
pared to the MR group. This result was probably due to
a better folate status through increased intake with the
MR, as demonstrated by the significant increase in
serum folic acid in the MR group.
In conclusion, both groups exhibited an effective
weight loss. Compliance was higher in the MR group
than in the C group as demonstrated by the higher
r e s p o n d e rr a t ei nt h eM R( 7 7 % )t h a ni nt h eCg r o u p
(50%). Cardiometabolic risk was positively affected
mainly through the decrease in BP, TC and LDL-C,
whereas other risk factors were not affected by the 12-
week dietary intervention. Systolic BP decreased to a
similar extent in both groups despite different influen-
cing variables. The significant lower serum homocys-
teine and higher folic acid after the 12-week dietary
intervention in the MR group was probably due to a
better folate status through increased intake with the
MR. Cardiometabolic risk profile improved only partly
in both groups.
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